88 related articles for article (PubMed ID: 38512672)
21. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification.
Barthélemy NR; Bateman RJ; Hirtz C; Marin P; Becher F; Sato C; Gabelle A; Lehmann S
Alzheimers Res Ther; 2020 Mar; 12(1):26. PubMed ID: 32183883
[TBL] [Abstract][Full Text] [Related]
22. Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains.
Arakhamia T; Lee CE; Carlomagno Y; Duong DM; Kundinger SR; Wang K; Williams D; DeTure M; Dickson DW; Cook CN; Seyfried NT; Petrucelli L; Fitzpatrick AWP
Cell; 2020 Feb; 180(4):633-644.e12. PubMed ID: 32032505
[TBL] [Abstract][Full Text] [Related]
23. Random coil chemical shifts for serine, threonine and tyrosine phosphorylation over a broad pH range.
Hendus-Altenburger R; Fernandes CB; Bugge K; Kunze MBA; Boomsma W; Kragelund BB
J Biomol NMR; 2019 Dec; 73(12):713-725. PubMed ID: 31598803
[TBL] [Abstract][Full Text] [Related]
24. Random coil shifts of posttranslationally modified amino acids.
Conibear AC; Rosengren KJ; Becker CFW; Kaehlig H
J Biomol NMR; 2019 Nov; 73(10-11):587-599. PubMed ID: 31317299
[TBL] [Abstract][Full Text] [Related]
25. Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer's Disease.
Barthélemy NR; Mallipeddi N; Moiseyev P; Sato C; Bateman RJ
Front Aging Neurosci; 2019; 11():121. PubMed ID: 31178717
[TBL] [Abstract][Full Text] [Related]
26. Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors.
Despres C; Di J; Cantrelle FX; Li Z; Huvent I; Chambraud B; Zhao J; Chen J; Chen S; Lippens G; Zhang F; Linhardt R; Wang C; Klärner FG; Schrader T; Landrieu I; Bitan G; Smet-Nocca C
ACS Chem Biol; 2019 Jun; 14(6):1363-1379. PubMed ID: 31046227
[TBL] [Abstract][Full Text] [Related]
27. Structural Basis of Tau Interaction With BIN1 and Regulation by Tau Phosphorylation.
Lasorsa A; Malki I; Cantrelle FX; Merzougui H; Boll E; Lambert JC; Landrieu I
Front Mol Neurosci; 2018; 11():421. PubMed ID: 30487734
[TBL] [Abstract][Full Text] [Related]
28. Crosstalk between phosphorylation and O-GlcNAcylation: friend or foe.
van der Laarse SAM; Leney AC; Heck AJR
FEBS J; 2018 Sep; 285(17):3152-3167. PubMed ID: 29717537
[TBL] [Abstract][Full Text] [Related]
29. Identification of the Tau phosphorylation pattern that drives its aggregation.
Despres C; Byrne C; Qi H; Cantrelle FX; Huvent I; Chambraud B; Baulieu EE; Jacquot Y; Landrieu I; Lippens G; Smet-Nocca C
Proc Natl Acad Sci U S A; 2017 Aug; 114(34):9080-9085. PubMed ID: 28784767
[TBL] [Abstract][Full Text] [Related]
30. FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease.
Mair W; Muntel J; Tepper K; Tang S; Biernat J; Seeley WW; Kosik KS; Mandelkow E; Steen H; Steen JA
Anal Chem; 2016 Apr; 88(7):3704-14. PubMed ID: 26877193
[TBL] [Abstract][Full Text] [Related]
31. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.
Morris M; Knudsen GM; Maeda S; Trinidad JC; Ioanoviciu A; Burlingame AL; Mucke L
Nat Neurosci; 2015 Aug; 18(8):1183-9. PubMed ID: 26192747
[TBL] [Abstract][Full Text] [Related]
32. Involvement of 14-3-3 in tubulin instability and impaired axon development is mediated by Tau.
Joo Y; Schumacher B; Landrieu I; Bartel M; Smet-Nocca C; Jang A; Choi HS; Jeon NL; Chang KA; Kim HS; Ottmann C; Suh YH
FASEB J; 2015 Oct; 29(10):4133-44. PubMed ID: 26103986
[TBL] [Abstract][Full Text] [Related]
33. Nuclear magnetic resonance spectroscopy characterization of interaction of Tau with DNA and its regulation by phosphorylation.
Qi H; Cantrelle FX; Benhelli-Mokrani H; Smet-Nocca C; Buée L; Lippens G; Bonnefoy E; Galas MC; Landrieu I
Biochemistry; 2015 Feb; 54(7):1525-33. PubMed ID: 25623359
[TBL] [Abstract][Full Text] [Related]
34. Oligomer formation of tau protein hyperphosphorylated in cells.
Tepper K; Biernat J; Kumar S; Wegmann S; Timm T; Hübschmann S; Redecke L; Mandelkow EM; Müller DJ; Mandelkow E
J Biol Chem; 2014 Dec; 289(49):34389-407. PubMed ID: 25339173
[TBL] [Abstract][Full Text] [Related]
35. Nuclear magnetic resonance analysis of the acetylation pattern of the neuronal Tau protein.
Kamah A; Huvent I; Cantrelle FX; Qi H; Lippens G; Landrieu I; Smet-Nocca C
Biochemistry; 2014 May; 53(18):3020-32. PubMed ID: 24708343
[TBL] [Abstract][Full Text] [Related]
36. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
[TBL] [Abstract][Full Text] [Related]
37. Cell signaling, post-translational protein modifications and NMR spectroscopy.
Theillet FX; Smet-Nocca C; Liokatis S; Thongwichian R; Kosten J; Yoon MK; Kriwacki RW; Landrieu I; Lippens G; Selenko P
J Biomol NMR; 2012 Nov; 54(3):217-36. PubMed ID: 23011410
[TBL] [Abstract][Full Text] [Related]
38. Tau protein kinases: involvement in Alzheimer's disease.
Martin L; Latypova X; Wilson CM; Magnaudeix A; Perrin ML; Yardin C; Terro F
Ageing Res Rev; 2013 Jan; 12(1):289-309. PubMed ID: 22742992
[TBL] [Abstract][Full Text] [Related]
39. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.
Yuzwa SA; Shan X; Macauley MS; Clark T; Skorobogatko Y; Vosseller K; Vocadlo DJ
Nat Chem Biol; 2012 Feb; 8(4):393-9. PubMed ID: 22366723
[TBL] [Abstract][Full Text] [Related]
40. Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein.
Sibille N; Huvent I; Fauquant C; Verdegem D; Amniai L; Leroy A; Wieruszeski JM; Lippens G; Landrieu I
Proteins; 2012 Feb; 80(2):454-62. PubMed ID: 22072628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
